Erythropoietic therapy: Dosing patterns and calculated cost assessment for pre-dialysis chronic kidney disease patients in a managed care setting

P and T

Volumn 32, Issue 12, 2007, Pages 661-670

  Barron, John J ^a   Grochulski, W Daniel ^a   Mody, Samir H ^b   Bookhart, Brahim K ^b   McKenzie, R Scott ^b  

^a HEALTHCORE INC   (United States)

^b Ortho Biotech Products LP   (United States)

Author keywords

Anemia; Chronic kidney disease; Cost; Darbepoetin alfa; Economic assessment; Epoetin alfa; Managed care

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DOSE CALCULATION; DRUG COST; FEMALE; HEALTH CARE COST; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; PATIENT CARE; RENAL REPLACEMENT THERAPY; TREATMENT DURATION;

EID: 38049049801     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. U.S. Renal Data System. 2005 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, Md: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2005.
2. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA 2007;298(17):2038-2047.
3. National Institutes of Health. Available at: www.nih.gov/news/pr/nov2007/ niddk-09.htm.
4. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154-2169.
5. McCullough PA, Lepor NE. The deadly triangle of anemia, renal insufficiency, and cardiovascular disease: Implications for prognosis and treatment. Rev Cardiovasc Med 2005;6:1-10.
6. Foley R, Parfrey P, Harnett J, et al. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 1996;28:53-61.
7. Sunder-Plassmann G, Horl W. Effect of erythropoietin on cardiovascular diseases. Am J Kidney Dis 2001;38:S20-S25.
8. Procrit (epoetin alfa) for injection, full prescribing information. Available at: www.procrit.com. Accessed November 19, 2007.
9. Epogen (epoetin alfa) for injection, prescribing information. Available at: www.epogen.com. Accessed November 19, 2007.
10. Aranesp (darbepoetin alfa) for injection, prescribing information. Available at: www.aranesp.com. Accessed November 19, 2007.
11. Provenzano R, Bhaduri S, Singh AK. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: The PROMPT study. Clin Nephrol 2005;64:113-123.
12. Toto RD, Pichette V, Navarro J, et al. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration. Am J Nephrol 2004;24(4):453-460.
13. Locatelli F, Olivares J, Walker R, et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 2001;60:741-747.
14. Smith DH, Gullion CM, Nichols G, et al. Cost of medical care for chronic kidney disease and comorbidity among enrollees in a large HMO population. J Am Soc Nephrol 2004;15:1300-1306.
15. London R, Solis A, Goldberg GA, et al. Healthcare resource utilization and the impact of anemia management in patients with chronic kidney disease. Am J Kidney Dis 2002;40:539-548.
16. London R, Solis A, Goldberg GA, et al. Examination of resource use and clinical interventions associated with chronic kidney disease in a managed care population. J Manag Care Pharm 2003;9:248-255.
17. Morreale A, Plowman B, DeLattre M, et al. Clinical and economic comparison of epoetin alfa and darbepoetin alfa. Curr Med Res Opin 2004;20:381-395.
18. Duh MS, Mody SH, McKenzie RS, et al. Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations. Clin Ther 2006;28(9):1443-1450.
19. Robinson DM, Easthope SE. Darbepoetin alfa: Its use in anemia associated with chronic kidney disease. BioDrugs 2005;19(5):327-343.
20. Benz R, Schmidt R, Kelly K, et al. Epoetin alfa once every 2 weeks is effective for initiation of treatment of anemia of chronic kidney disease. Clin J Am Soc Nephrol 2007;2:215-221.
21. Spinowitz B, Germain M, Benz R, et al. Extended dosing regimens for initiation of epoetin alfa for treatment of anemia of chronic kidney disease. Abstract 238. Poster, National Kidney Foundation 2007 Spring Clinical Meetings, April 10-14, 2007, Orlando, Fla. Am J Kidney Dis 2007;49(4):B84.
22. Germain M, Ram CV, Bhaduri S, et al. Extended epoetin alfa dosing in chronic kidney disease patients: A retrospective review. Nephrol Dial Transplant 2005;20:2146-2152.
23. Papatheofanis FJ, McKenzie RS, Mody SH, et al. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in predialysis chronic kidney disease patients with anemia. Curr Med Res Opin 2006; 22(5):837-842.
24. Papatheofanis F, Smith C, Mody S, et al. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in anemic predialysis chronic kidney disease patients from an observational study. Am J Ther 2007;14(4):322-327.
25. Ben-Hamadi R, Duh MS, Aggarwal J, et al. Cost-effectiveness of once weekly epoetin alfa and darbepoetin alfa in treating chemotherapy-induced anemia (Abstract CN1). Value Health 2005;8(3):238.
26. Chen E, Peake C, Buscaino E, et al. Hematologic outcomes and erythropoiesis-stimulating therapy costs in epoetin alfa (EPO)-and darbepoetin alfa (DARB)-treated cancer patients: Results of the Dosing and Outcomes Study of Erythropoiesis-stimulating therapies (D.O.S.E. Registry) (Abstract 3340). Poster, American Society of Hematology, 48th Annual Meeting and Exposition, December 9-12, 2006, Orlando, Fla. Blood 2006;108:953a.
27. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355(20):2085-2098.